{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:36:46Z","timestamp":1760985406783},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":15131,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1974,8]]},"abstract":"<jats:p>The absorption and clearance of secobarbital, heptabarbital, methaqualone, and ethinamate were studied by measurements of blood and plasma drug levels after single oral dosage in the therapeutic range to nonfasting sub;ects. Determinations of blood and plasma levels were carried out to the limits of sensitivity of the gas\u2010liquid chromatographic determination steps. The mean maximum plasma level of ethinamate was observed after 1 hour; that of methaqualone occurred after 2 hours; the mean maximum blood level of secobarbital was found after 3 hours, whereas that of heptabarbital was not observed until the sixth hour. Secobarbital was cleared slowly from the blood (the calculated half\u2010life was 28.9 hours); heptabarbital was faster (half\u2010life, 9.7 hours), and the half\u2010life of ethinamate was calculated as 2.3 hours. Methaqualone plasma levels decayed in a biphasic manner; the half\u2010life of the fast component was calculated as 0.9 hour and the slow one as 16 hours. Secobarbital, heptabarbital, and methaqualone could all be detected in the body 24 hours after they had been given.<\/jats:p>","DOI":"10.1002\/cpt1974162376","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T01:36:35Z","timestamp":1451957795000},"page":"376-389","source":"Crossref","is-referenced-by-count":20,"title":["Absorption and clearance of secobarbital, heptabarbital, methaqualone, and ethinamate"],"prefix":"10.1111","volume":"16","author":[{"given":"John M.","family":"Clifford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"Cookson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis E.","family":"Wickham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1974162376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1974162376","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt1974162376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:32:04Z","timestamp":1699363924000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt1974162376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1974,8]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1974,8]]}},"alternative-id":["10.1002\/cpt1974162376"],"URL":"https:\/\/doi.org\/10.1002\/cpt1974162376","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1974,8]]}}}